AGENUS INC Proceeds from License Fees Received
AGENUS INC (AGEN) reported Proceeds from License Fees Received of $6.25 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-11-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLicenseFeesReceived · last filed 2012-11-07
- AGENUS INC proceeds from license fees received for the quarter ending 2012-03-31 was $6.25M.
| Period end | Proceeds from License Fees Received 3 month |
|---|---|
| 2012-03-31 | $6.25M 10-Q · filed 2012-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |